Drug developer Depomed Inc said it will recall 52 lots of its diabetes drug Glumetza due to the presence of traces of a certain chemical in the tablet's 500 mg bottle.
The recall followed an investigation of a single product complaint of a smell and taste consistent with the chemical, the company said in a regulatory filing.
The chemical compound, 2,4,6-tribromoanisole (TBA), can cause temporary, non-serious gastrointestinal upset when present in amounts detectable by smell, the company said.
The recall does not impact the 1,000 mg formulation, which currently constitutes about 40 percent of total Glumetza net product sales, Depomed said.
Source/
